within Pharmacolibrary.Drugs.ATC.L;

model L04AB04
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.64,
    Cl             = 0.013 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 40 / 1000000,
    adminCount     = 1,
    Vd             = 0.005900000000000001,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.00018333333333333334,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Adalimumab is a fully human monoclonal antibody that binds specifically to tumor necrosis factor-alpha (TNF-α), blocking its interaction with the p55 and p75 cell surface TNF receptors. It is used to treat several autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and juvenile idiopathic arthritis. Adalimumab is approved and widely used today.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetic model in adult patients with rheumatoid arthritis after subcutaneous administration.</p><h4>References</h4><ol><li><p>Puig, L (2014). Methotrexate: new therapeutic approaches. <i>Actas dermo-sifiliograficas</i> 105(6) 583–589. DOI:<a href=&quot;https://doi.org/10.1016/j.ad.2012.11.017&quot;>10.1016/j.ad.2012.11.017</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/23434058/&quot;>https://pubmed.ncbi.nlm.nih.gov/23434058</a></p></li><li><p>Oyama, S, et al., &amp; Nakata, K (2022). A novel anti-TNF-α drug ozoralizumab rapidly distributes to inflamed joint tissues in a mouse model of collagen induced arthritis. <i>Scientific reports</i> 12(1) 18102–None. DOI:<a href=&quot;https://doi.org/10.1038/s41598-022-23152-6&quot;>10.1038/s41598-022-23152-6</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36302840/&quot;>https://pubmed.ncbi.nlm.nih.gov/36302840</a></p></li><li><p>Ternant, D, et al., &amp; Paintaud, G (2015). Pharmacokinetics and concentration-effect relationship of adalimumab in rheumatoid arthritis. <i>British journal of clinical pharmacology</i> 79(2) 286–297. DOI:<a href=&quot;https://doi.org/10.1111/bcp.12509&quot;>10.1111/bcp.12509</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25223394/&quot;>https://pubmed.ncbi.nlm.nih.gov/25223394</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L04AB04;
